Timothy Kutzkey
Director/Board Member bij SURROZEN, INC.
Vermogen: 23 850 $ op 31-03-2024
Profiel
Timothy W.
Kutzkey was the founder of Nurix Therapeutics, Inc. (founded in 2009) and held the title of Chairman from 2016 to 2019.
He is also the founder of Nura Bio, Inc., Kimia Therapeutics, Inc...
Dr. Kutzkey's current job(s) include being the Chairman of Neurona Therapeutics, Inc., Carmot Therapeutics, Inc., and the Director of Kallyope, Inc., Plexium, Inc., Synthekine, Inc., Cajal Neuroscience, Inc., Surrozen, Inc., and InduPro, Inc. Dr. Kutzkey's former job(s) include being the President, Chief Executive Officer & Director of Peloton Therapeutics, Inc., the Chief Executive Officer & Director of Surrozen Operating, Inc., the Chief Executive Officer & Secretary of Proneurotech, Inc., and a Director of Cyterix Pharmaceuticals, Inc. He was also a Principal at KAI Pharmaceuticals, Inc. from 2006 to 2007.
Dr. Kutzkey obtained his undergraduate degree from Stanford University in 1997 and his doctorate degree from the University of California, Berkeley in 2005.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 28-12-2023 | 15 000 ( 0.02% ) | 23 850 $ | 31-03-2024 | |
SURROZEN INC
-.--% | 04-04-2024 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Timothy Kutzkey
| Bedrijven | Functie | Begin |
|---|---|---|
| SURROZEN, INC. | Director/Board Member | 01-04-2016 |
The Column Group LLC
 The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Private Equity Investor | 01-01-2007 |
Carmot Therapeutics, Inc.
 Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Chairman | 01-04-2010 |
InduPro, Inc.
 InduPro, Inc. BiotechnologyHealth Technology InduPro, Inc. engages in integrating inherent protein proximity at the cell surface and translates biological insights into transformative therapeutics. The company is based in San Francisco, CA. The company was founded by K. Christopher Garcia. | Director/Board Member | - |
Cajal Neuroscience, Inc.
 Cajal Neuroscience, Inc. BiotechnologyHealth Technology Cajal Neuroscience is a biotechnology company that focuses on discovering new treatments for neurodegeneration. The company is based in Seattle, WA and was founded by Ian Peikon. The company uses advanced technologies such as integrative human genetics, multi-omics, functional genomics, and microscopy to accelerate their target and drug discovery. | Director/Board Member | - |
Plexium, Inc.
 Plexium, Inc. Pharmaceuticals: MajorHealth Technology Plexium, Inc. provides drug development methodology services. It specializes in immunomodulation as a therapeutic approach for CNS and oncology. The company was founded by Brian Paegel on July 12, 2017 and is headquartered in San Diego, CA. | Director/Board Member | - |
Nura Bio, Inc.
 Nura Bio, Inc. Pharmaceuticals: MajorHealth Technology Nura Bio, Inc. develops neuroprotective drugs. The company is headquartered in South San Francisco, CA. | Founder | - |
Synthekine, Inc.
 Synthekine, Inc. BiotechnologyHealth Technology Synthekine, Inc. engages as a biotechnology company. The company is headquartered in Menlo Park, CA. | Director/Board Member | - |
Kallyope, Inc.
 Kallyope, Inc. Medical/Nursing ServicesHealth Services Kallyope, Inc. engages in developing drugs and consumer products. Its specialties include biotechnology, gut-brain axis, nutrition, and pharmaceuticals. The company was founded by Thomas P. Maniatis, Charles Zuker and Richard Axel in 2014 and is headquartered in New York, NY. | Director/Board Member | - |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | - |
Eerdere bekende functies van Timothy Kutzkey
| Bedrijven | Functie | Einde |
|---|---|---|
| ░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
| ░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
| ░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | - |
| ░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Timothy Kutzkey
| Stanford University | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| NURIX THERAPEUTICS, INC. | Health Technology |
| SURROZEN, INC. | Health Technology |
| Bedrijven in privébezit | 14 |
|---|---|
KAI Pharmaceuticals, Inc.
 KAI Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology KAI Pharmaceuticals, Inc. discovers and develops biopharmaceutical drugs. It is a multiple, novel clinical-stage programs in the areas of cardiovascular, renal, and pain. The company was founded in 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Neurona Therapeutics, Inc.
 Neurona Therapeutics, Inc. BiotechnologyHealth Technology Neurona Therapeutics, Inc. operates as a pre-clinical stage biotechnology company. It focuses on the discovery and development of cell-based therapies to treat intractable neurological disease. The company was founded by Arnold R. Kriegstein, John Rubenstein, Cory R. Nicholas, and Arturo Alvarez-Buylla and is headquartered in South San Francisco, CA. | Health Technology |
Cyterix Pharmaceuticals, Inc.
 Cyterix Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Cyterix Pharmaceuticals, Inc. develops cancer therapeutics. It develops cancer therapeutics based on a proprietary OncoCY prodrug discovery approach. The company was founded by Paul R. Ortiz De Montellano, Luis Bayol and Steven A. Everett on April 10, 2010 and is headquartered in San Francisco, CA. | Health Technology |
Peloton Therapeutics, Inc.
 Peloton Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Peloton Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in translating novel scientific insights into medicines for patients with cancer and other debilitating or life-threatening conditions. Its lead drug candidate is a small molecule which targets HIF-2a, a transcription factor implicated in the development and progression of renal and other cancers. The company was founded by Steven L. McKnight in August 2010 and is headquartered in Dallas, TX. | Health Technology |
The Column Group LLC
The Column Group LLC Investment ManagersFinance The Column Group LLC is a venture capital firm founded in 2005 by Peter Svennilson. The firm is headquartered in San Francisco. | Finance |
Carmot Therapeutics, Inc.
Carmot Therapeutics, Inc. BiotechnologyHealth Technology Carmot Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of therapeutics for metabolic diseases, cancer, and inflammation. Its pipeline includes CT-388, CT-996, and CT-868. The CT-388 refers to treatment taken once-weekly subcutaneous injectable for obesity and type 2 diabetes (T2D). The CT-996 comprises of once-daily oral treatment for obesity and T2D. The CT-868 consists of once-daily subcutaneous injectable for treatment of type 1 diabetes (T1D) patients with overweight or obesity. The company was founded in 2008 and is headquartered in Berkeley, CA. | Health Technology |
Kallyope, Inc.
Kallyope, Inc. Medical/Nursing ServicesHealth Services Kallyope, Inc. engages in developing drugs and consumer products. Its specialties include biotechnology, gut-brain axis, nutrition, and pharmaceuticals. The company was founded by Thomas P. Maniatis, Charles Zuker and Richard Axel in 2014 and is headquartered in New York, NY. | Health Services |
Surrozen Operating, Inc.
 Surrozen Operating, Inc. BiotechnologyHealth Technology Surrozen Operating, Inc. operates as a biopharmaceutical company that focuses on harnessing the Wnt pathway for applications in regenerative medicine. The firm implements a surrogate Wnt platform with the potential to unlock stem cell control in an array of human tissues. The company was founded by K. Christopher Garcia, Roeland Nusse, Calvin J. Kuo, Hans Claudia and Claudia Janda in 2015 and is headquartered in South San Francisco, CA. | Health Technology |
Plexium, Inc.
Plexium, Inc. Pharmaceuticals: MajorHealth Technology Plexium, Inc. provides drug development methodology services. It specializes in immunomodulation as a therapeutic approach for CNS and oncology. The company was founded by Brian Paegel on July 12, 2017 and is headquartered in San Diego, CA. | Health Technology |
Synthekine, Inc.
Synthekine, Inc. BiotechnologyHealth Technology Synthekine, Inc. engages as a biotechnology company. The company is headquartered in Menlo Park, CA. | Health Technology |
Nura Bio, Inc.
Nura Bio, Inc. Pharmaceuticals: MajorHealth Technology Nura Bio, Inc. develops neuroprotective drugs. The company is headquartered in South San Francisco, CA. | Health Technology |
Cajal Neuroscience, Inc.
Cajal Neuroscience, Inc. BiotechnologyHealth Technology Cajal Neuroscience is a biotechnology company that focuses on discovering new treatments for neurodegeneration. The company is based in Seattle, WA and was founded by Ian Peikon. The company uses advanced technologies such as integrative human genetics, multi-omics, functional genomics, and microscopy to accelerate their target and drug discovery. | Health Technology |
InduPro, Inc.
InduPro, Inc. BiotechnologyHealth Technology InduPro, Inc. engages in integrating inherent protein proximity at the cell surface and translates biological insights into transformative therapeutics. The company is based in San Francisco, CA. The company was founded by K. Christopher Garcia. | Health Technology |
Kimia Therapeutics, Inc.
 Kimia Therapeutics, Inc. BiotechnologyHealth Technology Kimia Therapeutics, Inc. is a drug discovery company that utilizes high throughput precision chemistry, genome editing, and machine learning to identify druggable sites for human disease intervention. The private company is based in Berkeley, CA. The company is building a next-generation therapeutics discovery platform called Atlas, which combines active learning with automated synthesis and screening. Atlas is powered by a high-throughput, nano-liter scale chemistry platform that provides Kimia with instant access to billions of drug-like compounds. The CEO of the company is Stig K. Hansen. | Health Technology |
